NASDAQ:OLMA - Olema Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $60.67
  • Forecasted Upside: 72.30 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$35.21
▲ +1.66 (4.95%)
1 month | 3 months | 12 months
Get New Olema Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OLMA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OLMA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$60.67
▲ +72.30% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Olema Pharmaceuticals in the last 3 months. The average price target is $60.67, with a high forecast of $70.00 and a low forecast of $52.00. The average price target represents a 72.30% upside from the last price of $35.21.
Buy
The current consensus among 4 polled investment analysts is to buy stock in Olema Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/14/2020JPMorgan Chase & Co.Initiated CoverageOverweight$52.00High
i
12/14/2020Jefferies Financial GroupInitiated CoverageBuy$70.00High
i
12/14/2020Canaccord GenuityInitiated CoverageBuy$60.00High
i
12/14/2020CowenInitiated CoverageOutperformHigh
i
(Data available from 4/22/2016 forward)
Olema Pharmaceuticals logo
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $35.21
$32.42
$36.18

50 Day Range

MA: $37.11
$27.81
$49.67

52 Week Range

Now: $35.21
$26.74
$60.27

Volume

72,539 shs

Average Volume

146,731 shs

Market Capitalization

$1.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Olema Pharmaceuticals?

The following Wall Street research analysts have issued research reports on Olema Pharmaceuticals in the last year: Canaccord Genuity, Cowen Inc, Jefferies Financial Group Inc., JPMorgan Chase & Co., and Zacks Investment Research.
View the latest analyst ratings for OLMA.

What is the current price target for Olema Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Olema Pharmaceuticals in the last year. Their average twelve-month price target is $60.67, suggesting a possible upside of 72.3%. Jefferies Financial Group Inc. has the highest price target set, predicting OLMA will reach $70.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $52.00 for Olema Pharmaceuticals in the next year.
View the latest price targets for OLMA.

What is the current consensus analyst rating for Olema Pharmaceuticals?

Olema Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OLMA will outperform the market and that investors should add to their positions of Olema Pharmaceuticals.
View the latest ratings for OLMA.

What other companies compete with Olema Pharmaceuticals?

How do I contact Olema Pharmaceuticals' investor relations team?

Olema Pharmaceuticals' physical mailing address is 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107. The company's listed phone number is 415-651-3316 and its investor relations email address is [email protected] The official website for Olema Pharmaceuticals is www.olema.com.